FDA-Industry GDUFA II Reauthorization Meeting - Small Business Subgroup December 1, 2015: 2:00pm – 5:00pm FDA White Oak Campus, Silver Spring, MD Building 75, Room 6600

Purpose:

Kickoff meeting for Small Business sub-group. Set sub-group goals and expectations.

Participants:

<u>FDA</u>		<u>Industry</u>	Industry	
Mike Jones	CDER	Lisa Tan	GPhA	
Rob Berlin	OC	David Ga	augh GPhA	
Kirk Kerr	CDER	Keith We	ebber GPhA	
Carter Beach	CDER	Alan Nicl	holls BPTF	
Thomas Henry	OC	Tom Tho	orpe PBOA	

Discussion of small business working group goals

FDA and Industry representatives discussed the objectives of the working group in that Congress directed all stakeholders to consider relief for small businesses during the GDUFA reauthorization process. This subgroup will discuss potential options and present them back to the GDUFA II negotiators.

Discussion of generic drug small business landscape

The sub-group discussed the generic drug landscape including how to define a small business within the industry. It was noted that possible solutions should be easy to operationalize and that relief for one segment of the industry would require increased fees from all others.

Discussion of next steps and upcoming meetings

The sub-group has scheduled additional meetings. At the next meeting, Industry has agreed to propose potential options for small business relief.